Side effects and perceptions following Sinopharm COVID-19 vaccination

International Journal of Infectious Diseases, Journal Year: 2021, Volume and Issue: 111, P. 219 - 226

Published: Aug. 9, 2021

ObjectivesVaccines are one of the best interventions developed for eradicating COVID-19. This study aimed to provide evidence on Sinopharm COVID-19 vaccine side effects.MethodsA cross-sectional survey was conducted between January and April 2021 collect data effects among individuals in United Arab Emirates. Demographic data, vaccination response people unwilling take were reported.ResultsSide post first dose normal injection site pain, fatigue headache more common participants aged ≤49 years versus >49 years, while pain at site, fatigue, lethargy, tenderness most second both groups. All doses prevalent years. Side females compared with males doses. The reason being that vaccines not effective.ConclusionPost-vaccination mild predictable, there no hospitalization cases; this will help reduce hesitancy.

Language: Английский

---

Vaccination induces HIV broadly neutralizing antibody precursors in humans

Science, Journal Year: 2022, Volume and Issue: 378(6623)

Published: Dec. 1, 2022

Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B cells. In a randomized, double-blind, placebo-controlled phase 1 clinical trial, the vaccine-priming candidate eOD-GT8 60mer adjuvanted with AS01

Language: Английский

---

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(6), P. 802 - 812

Published: March 7, 2022

Language: Английский

---

COVID-19 Vaccines and the Skin

Dermatologic Clinics, Journal Year: 2021, Volume and Issue: 39(4), P. 653 - 673

Published: May 31, 2021

Language: Английский

---

Can a COVID-19 vaccine live up to Americans’ expectations? A conjoint analysis of how vaccine characteristics influence vaccination intentions

Social Science & Medicine, Journal Year: 2021, Volume and Issue: 272, P. 113642 - 113642

Published: Jan. 4, 2021

Language: Английский

---

A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: May 31, 2021

Although inoculation of COVID-19 vaccines has rolled out globally, there is still a critical need for safe and effective to ensure fair equitable supply all countries. Here, we report on the development highly efficacious mRNA vaccine, SW0123 that composed sequence-modified encoding full-length SARS-CoV-2 Spike protein packaged in core-shell structured lipopolyplex (LPP) nanoparticles. easy produce using large-scale microfluidics-based apparatus. The unique nanoparticle facilitates vaccine uptake demonstrates high colloidal stability, desirable biodistribution pattern with low liver targeting effect upon intramuscular administration. Extensive evaluations mice nonhuman primates revealed strong immunogenicity SW0123, represented by induction Th1-polarized T cell responses levels antibodies were capable neutralizing not only wild-type SARS-CoV-2, but also panel variants including D614G N501Y variants. In addition, conferred protection both non-human challenge. Taken together, promising candidate holds prospects further evaluation humans.

Language: Английский

---

Vaccines for human fungal diseases: close but still a long way to go

npj Vaccines, Journal Year: 2021, Volume and Issue: 6(1)

Published: March 3, 2021

Abstract Despite the substantial global burden of human fungal infections, there are no approved vaccines to protect at risk individuals. Here, we review progress that has been made and challenges lie ahead in quest towards efficacious vaccines. In mouse studies, protection achieved with directed against pathogens, including species Candida, Cryptococcus , Aspergillus most commonly cause life-threatening disease. Encouraging results have obtained composed live-attenuated killed fungi, crude extracts, recombinant subunit formulations, nucleic acid Novel adjuvants instruct immune system mount types protective responses needed fight mycotic infections under development. Candidate include those target common antigens expressed on multiple genera fungi thereby protecting a broad range mycoses. Encouragingly, three reached clinical trials. Still, formidable obstacles must be overcome before will licensed for use.

Language: Английский

---

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

Clinical Immunology, Journal Year: 2021, Volume and Issue: 229, P. 108786 - 108786

Published: June 18, 2021

Language: Английский

---

Vaccine Side Effects Following COVID-19 Vaccination Among the Residents of the UAE—An Observational Study

Frontiers in Public Health, Journal Year: 2022, Volume and Issue: 10

Published: May 6, 2022

COVID-19 vaccines have proven to be very safe in the clinical trials, however, there is less evidence comparing safety of these real-world settings. Therefore, we aim investigate nature and severity adverse effects reported differences based on type vaccine received. A survey was conducted among 1,878 adult (≥18 years) recipients through online platforms telephonic interviews during March September 2021. The factors potentially associated with side like age, gender, ethnicity, comorbidities, previous infection were analyzed Differences events compared between inactivated mRNA recipients. major by pain at site injection, fatigue drowsiness, headache followed joint/muscle pain. more common Pfizer-BioNTech than inactive Sinopharm odds ratio 1.39 (95% CI 1.14–1.68). average number individuals who had received 1.61 ± 2.08 2.20 2.58, respectively, difference statistically significant ( p <0.001). Severe after vaccinations rare 95% either an or mild requiring no home-based treatment. study found that 55 years female history one comorbid conditions, Pfizer- BioNTech vaccine, infections are higher developing effect post vaccination others.

Language: Английский

---

Potential for Maternally Administered Vaccine for Infant Group B Streptococcus

New England Journal of Medicine, Journal Year: 2023, Volume and Issue: 389(3), P. 215 - 227

Published: July 19, 2023

Natural history studies have correlated serotype-specific anti-capsular polysaccharide (CPS) IgG in newborns with a reduced risk of group B streptococcal disease. A hexavalent CPS-cross-reactive material 197 glycoconjugate vaccine (GBS6) is being developed as maternal to prevent invasive streptococcus young infants.

Language: Английский

---